Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 150-166

  Wong, Henry K ^a   Mishra, Anjali ^a   Hake, Timothy ^a   Porcu, Pierluigi ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cutaneous T cell lymphoma; Cytokines; Interleukin 15; Mycosis fungoides; Sezary syndrome

Indexed keywords

AGATOLIMOD; ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZACITIDINE; BELINOSTAT; BEXAROTENE; BORTEZOMIB; DENILEUKIN DIFTITOX; DOXORUBICIN; FORODESINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; INTERFERON; PANOBINOSTAT; PEGINTERFERON ALPHA2B; PENTOSTATIN; PLACEBO; PRALATREXATE; PSORALEN; RETINOIC ACID; RETINOID; ROMIDEPSIN; SIPLIZUMAB; VORINOSTAT; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER INCIDENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLOR VISION DEFECT; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FLU LIKE SYNDROME; GENOMIC INSTABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOTHYROIDISM; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEUKOPENIA; LIVER FUNCTION; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MUCOCUTANEOUS SYMPTOM; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYALGIA; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PRURITUS; PUVA; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RIGOR; SEZARY SYNDROME; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN DISEASE; SKIN REDNESS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TRANSCRIPTOMICS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; VISUAL IMPAIRMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE PROGRESSION; GENES, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; MICE; MULTICENTER STUDIES AS TOPIC; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053571383     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08852.x     Document Type: Review

References (197)

1. Agar, N.S., Wedgeworth, E., Crichton, S., Mitchell, T.J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C.M., Wain, E.M., Wilkins, B., Fields, P.A., Dean, A., Webb, K., Scarisbrick, J., Morris, S. & Whittaker, S.J. (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology, 28, 4730-4739.
2. Alibert, J. (1806) Description des maladies de la peau observées a l'Hôpital Saint-Louis, et exposition des meilleures méthodes suivies pour leur traitement. Barrois l'aine, Paris.
3. Alinari, L., Geskin, L., Grady, T., Baiocchi, R.A., Bechtel, M.A. & Porcu, P. (2008) Subcutaneous alemtuzumab for Sezary Syndrome in the very elderly. Leukemia Research, 32, 1299-1303.
4. Asadullah, K., Docke, W.D., Haeussler, A., Sterry, W. & Volk, H.D. (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. Journal of Investigative Dermatology, 107, 833-837.
5. Asadullah, K., Haeussler-Quade, A., Gellrich, S., Hanneken, S., Hansen-Hagge, T.E., Docke, W.D., Volk, H.D. & Sterry, W. (2000) IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Experimental Dermatology, 9, 248-251.
6. Assaf, C., Bagot, M., Dummer, R., Duvic, M., Gniadecki, R., Knobler, R., Ranki, A., Schwandt, P. & Whittaker, S. (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. British Journal of Dermatology, 155, 261-266.
7. Axelrod, P.I., Lorber, B. & Vonderheid, E.C. (1992) Infections complicating mycosis fungoides and Sezary syndrome. Journal of American Medical Association, 267, 1354-1358.
8. Bahler, D.W., Hartung, L., Hill, S., Bowen, G.M. & Vonderheid, E.C. (2008) CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry. Cytometry Part B: Clinical Cytometry, 74, 156-162.
9. Balakrishnan, K., Nimmanapalli, R., Ravandi, F., Keating, M.J. & Gandhi, V. (2006) Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 108, 2392-2398.
10. Balakrishnan, K., Verma, D., O'Brien, S., Kilpatrick, J.M., Chen, Y., Tyler, B.F., Bickel, S., Bantia, S., Keating, M.J., Kantarjian, H., Gandhi, V. & Ravandi, F. (2010) Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood, 116, 886-892.
11. Ballabio, E., Mitchell, T., van Kester, M.S., Taylor, S., Dunlop, H.M., Chi, J., Tosi, I., Vermeer, M.H., Tramonti, D., Saunders, N.J., Boultwood, J., Wainscoat, J.S., Pezzella, F., Whittaker, S.J., Tensen, C.P., Hatton, C.S. & Lawrie, C.H. (2010) MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood, 116, 1105-1113.
12. Berger, C.L., Tigelaar, R., Cohen, J., Mariwalla, K., Trinh, J., Wang, N. & Edelson, R.L. (2005) Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood, 105, 1640-1647.
13. Bernengo, M.G., Quaglino, P., Comessatti, A., Ortoncelli, M., Novelli, M., Lisa, F. & Fierro, M.T. (2007) Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica, 92, 784-794.
14. Blagosklonny, M.V., Robey, R., Sackett, D.L., Du, L., Traganos, F., Darzynkiewicz, Z., Fojo, T. & Bates, S.E. (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Molecular Cancer Therapeutics, 1, 937-941.
15. de Bono, J.S., Kristeleit, R., Tolcher, A., Fong, P., Pacey, S., Karavasilis, V., Mita, M., Shaw, H., Workman, P., Kaye, S., Rowinsky, E.K., Aherne, W., Atadja, P., Scott, J.W. & Patnaik, A. (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clinical Cancer Research, 14, 6663-6673.
16. Booken, N., Gratchev, A., Utikal, J., Weiss, C., Yu, X., Qadoumi, M., Schmuth, M., Sepp, N., Nashan, D., Rass, K., Tuting, T., Assaf, C., Dippel, E., Stadler, R., Klemke, C.D. & Goerdt, S. (2008) Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia, 22, 393-399.
17. Bradford, P.T., Devesa, S.S., Anderson, W.F. & Toro, J.R. (2009) Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood, 113, 5064-5073.
18. Buglio, D. & Younes, A. (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Investigational New Drugs, 28(Suppl 1), S21-S27.
19. Burg, G., Dummer, R., Haeffner, A., Kempf, W. & Kadin, M. (2001) From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Archives of Dermatology, 137, 949-952.
20. Burnet, M. (1957) Cancer; a biological approach. I. The processes of control. British Medical Journal, 1, 779-786.
21. Caprini, E., Cristofoletti, C., Arcelli, D., Fadda, P., Citterich, M., Sampogna, F., Magrelli, A., Censi, F., Torreri, P., Frontani, M., Scala, E., Picchio, M.C., Temperani, P., Monopoli, A., Lombardo, G.A., Taruscio, D. & Narducci, M.G. (2009) Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. Cancer Research, 68, 137-146.
22. Capriotti, E., Vonderheid, E.C., Thoburn, C.J., Wasik, M.A., Bahler, D.W. & Hess, A.D. (2008) Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leukemia and Lymphoma, 49, 1190-1201.
23. Chaturvedi, M.M., Sung, B., Yadav, V.R., Kannappan, R. & Aggarwal, B.B. (2011) NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene, 30, 1615-1630.
24. Chong, B.F., Wilson, A.J., Gibson, H.M., Hafner, M.S., Luo, Y., Hedgcock, C.J. & Wong, H.K. (2008) Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clinical Cancer Research, 14, 646-653.
25. Chong, B.F., Dantzer, P., Germeroth, T., Hafner, M., Wilson, A.J., Xiao, G. & Wong, H.K. (2010) Induced Sezary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells. Journal of Dermatologic Science, 60, 8-20.
26. Chott, A., Vonderheid, E.C., Olbricht, S., Miao, N.N., Balk, S.P. & Kadin, M.E. (1996) The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. Journal Investigative Dermatology, 106, 696-700.
27. Ciree, A., Michel, L., Camilleri-Broet, S., Jean Louis, F., Oster, M., Flageul, B., Senet, P., Fossiez, F., Fridman, W.H., Bachelez, H. & Tartour, E. (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). International Journal of Cancer, 112, 113-120.
28. Criscione, V.D. & Weinstock, M.A. (2007) Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology, 143, 854-859.
29. Crowley, J.J., Nikko, A., Varghese, A., Hoppe, R.T. & Kim, Y.H. (1998) Mycosis fungoides in young patients: clinical characteristics and outcome. Journal of American Academy of Dermatology, 38, 696-701.
30. Dearden, C.E. & Matutes, E. (2006) Alemtuzumab in T-cell lymphoproliferative disorders. Best practice & research. Clinical Haematology, 19, 795-810.
31. Deeths, M.J., Chapman, J.T., Dellavalle, R.P., Zeng, C. & Aeling, J.L. (2005) Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. Journal of the American Academy of Dermatology, 52, 275-280.
32. Dighe, A.S., Richards, E., Old, L.J. & Schreiber, R.D. (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity, 1, 447-456.
33. Dobbeling, U., Dummer, R., Laine, E., Potoczna, N., Qin, J.Z. & Burg, G. (1998) Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood, 92, 252-258.
34. Dooms, H., Desmedt, M., Vancaeneghem, S., Rottiers, P., Goossens, V., Fiers, W. & Grooten, J. (1998) Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen. Journal of Immunology, 161, 2141-2150.
35. van Doorn, R., Van Haselen, C.W., van Voorst Vader, P.C., Geerts, M.L., Heule, F., de Rie, M., Steijlen, P.M., Dekker, S.K., van Vloten, W.A. & Willemze, R. (2000) Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Archives of Dermatology, 136, 504-510.
36. van Doorn, R., Dijkman, R., Vermeer, M.H., Out-Luiting, J.J., van der Raaij-Helmer, E.M., Willemze, R. & Tensen, C.P. (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Research, 64, 5578-5586.
37. van Doorn, R., Zoutman, W.H., Dijkman, R., de Menezes, R.X., Commandeur, S., Mulder, A.A., van der Velden, P.A., Vermeer, M.H., Willemze, R., Yan, P.S., Huang, T.H. & Tensen, C.P. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. Journal of Clinical Oncology, 23, 3886-3896.
38. van Doorn, R., van Kester, M.S., Dijkman, R., Vermeer, M.H., Mulder, A.A., Szuhai, K., Knijnenburg, J., Boer, J.M., Willemze, R. & Tensen, C.P. (2009) Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood, 113, 127-136.
39. Duarte, R.F., Schmitz, N., Servitje, O. & Sureda, A. (2008) Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplantation, 41, 597-604.
40. Duarte, R.F., Canals, C., Onida, F., Gabriel, I.H., Arranz, R., Arcese, W., Ferrant, A., Kobbe, G., Narni, F., Deliliers, G.L., Olavarria, E., Schmitz, N. & Sureda, A. (2010) Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 28, 4492-4499.
41. Dummer, R., Heald, P.W., Nestle, F.O., Ludwig, E., Laine, E., Hemmi, S. & Burg, G. (1996) Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood, 88, 1383-1389.
42. Dummer, R., Geertsen, R., Ludwig, E., Niederer, E. & Burg, G. (1998) Sezary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leukemia and Lymphoma, 28, 515-522.
43. Dummer, R., Urosevic, M., Kempf, W., Kazakov, D. & Burg, G. (2003) Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology, 207, 116-118.
44. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3, 991-998.
45. Dunn, G.P., Koebel, C.M. & Schreiber, R.D. (2006) Interferons, immunity and cancer immunoediting. Nature Review Immunology, 6, 836-848.
46. Duvic, M., Martin, A.G., Kim, Y., Olsen, E., Wood, G.S., Crowley, C.A., Yocum, R.C. & Worldwide Bexarotene Study. (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology, 137, 581-593.
47. Duvic, M., Kuzel, T.M., Olsen, E.A., Martin, A.G., Foss, F.M., Kim, Y.H., Heald, P.W., Bacha, P., Nichols, J. & Liepa, A. (2002) Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma and Myeloma, 2, 222-228.
48. Duvic, M., Talpur, R., Wen, S., Kurzrock, R., David, C.L. & Apisarnthanarax, N. (2006a) Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clinical Lymphoma and Myeloma, 7, 51-58.
49. Duvic, M., Forero, A., Foss, F., Olsen, E. & Kim, Y. (2006b) Oral Forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study. Blood, 108, 2467.
50. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., Richon, V.M. & Frankel, S.R. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109, 31-39.
51. Edelson, R.L. (2001) Cutaneous T cell lymphoma: the helping hand of dendritic cells. Annals of the New York Academy of Science, 941, 1-11.
52. Ehlers, S. & Smith, K.A. (1991) Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. Journal of Experimental Medicine, 173, 25-36.
53. Ellis, L., Pan, Y., Smyth, G.K., George, D.J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., Atadja, P., Butterfoss, D., Dugan, M., Culver, K., Johnstone, R.W. & Prince, H.M. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research, 14, 4500-4510.
54. Fehniger, T.A., Suzuki, K., Ponnappan, A., VanDeusen, J.B., Cooper, M.A., Florea, S.M., Freud, A.G., Robinson, M.L., Durbin, J. & Caligiuri, M.A. (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. Journal Experimental Medicine, 193, 219-231.
55. Fishwild, D.M., O'Donnell, S.L., Bengoechea, T., Hudson, D.V., Harding, F., Bernhard, S.L., Jones, D., Kay, R.M., Higgins, K.M., Schramm, S.R. & Lonberg, N. (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnology, 14, 845-851.
56. Foss, F. (2006) Clinical experience with denileukin diftitox (ONTAK). Seminars in Oncology, 33, S11-S16.
57. Frampton, J.E. & Wagstaff, A.J. (2003) Alemtuzumab. Drugs, 63, 1229-1243; discussion 1245-1226.
58. Gandhi, V. & Balakrishnan, K. (2007) Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Seminars in oncology, 34, S8-S12.
59. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V.R., Randolph, S.S., Hardwick, J.S., Reilly, J.F., Chen, C., Ricker, J.L., Secrist, J.P., Richon, V.M., Frankel, S.R. & Kantarjian, H.M. (2008a) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111, 1060-1066.
60. Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W.M., Miller, Jr, W.H., Rousseau, C., Kalita, A., Bonfils, C., Dubay, M., Patterson, T.A., Li, Z., Besterman, J.M., Reid, G., Laille, E., Martell, R.E. & Minden, M. (2008b) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 112, 981-989.
61. Garzon, R., Marcucci, G. & Croce, C.M. (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Review Drug Discovery, 9, 775-789.
62. Gazdar, A.F., Carney, D.N., Russell, E.K., Schechter, G.P. & Bunn, Jr, P.A. (1979) In vitro growth of cutaneous T-cell lymphomas. Cancer Treatment Reports, 63, 587-590.
63. Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., Kantarjian, H., Dugan, M., Albitar, M. & Bhalla, K. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research, 12, 4628-4635.
64. Gimsing, P., Hansen, M., Knudsen, L.M., Knoblauch, P., Christensen, I.J., Ooi, C.E. & Buhl-Jensen, P. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology, 81, 170-176.
65. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J. & Catovsky, D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research, 22, 185-191.
66. Girardi, M., Heald, P.W. & Wilson, L.D. (2004) The pathogenesis of mycosis fungoides. New England Journal of Medicine, 350, 1978-1988.
67. Gore, L., Rothenberg, M.L., O'Bryant, C.L., Schultz, M.K., Sandler, A.B., Coffin, D., McCoy, C., Schott, A., Scholz, C. & Eckhardt, S.G. (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clinical Cancer Research, 14, 4517-4525.
68. Goronzy, J.J. & Weyand, C.M. (2003) Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Research and Therapy, 5, 225-234.
69. Greiner, D., Olsen, E.A. & Petroni, G. (1997) Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 36, 950-955.
70. Hahtola, S., Tuomela, S., Elo, L., Hakkinen, T., Karenko, L., Nedoszytko, B., Heikkila, H., Saarialho-Kere, U., Roszkiewicz, J., Aittokallio, T., Lahesmaa, R. & Ranki, A. (2006) Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clinical Cancer Research, 12, 4812-4821.
71. Hallermann, C., Kaune, K.M., Tiemann, M., Kunze, E., Griesinger, F., Mitteldorf, C., Bertsch, H.P. & Neumann, C. (2007) High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Annals of Hematology, 86, 509-515.
72. Hodak, E., Klein, T., Gabay, B., Ben-Amitai, D., Bergman, R., Gdalevich, M., Feinmesser, M., Maron, L. & David, M. (2005) Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system. Journal of the American Academy of Dermatology, 52, 393-402.
73. Hoppe, R.T., Medeiros, L.J., Warnke, R.A. & Wood, G.S. (1995) CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. Journal of the American Academy of Dermatology, 32, 448-453.
74. Hwang, S.T., Janik, J.E., Jaffe, E.S. & Wilson, W.H. (2008) Mycosis fungoides and Sezary syndrome. Lancet, 371, 945-957.
75. Ito, A., Ishida, T., Yano, H., Inagaki, A., Suzuki, S., Sato, F., Takino, H., Mori, F., Ri, M., Kusumoto, S., Komatsu, H., Iida, S., Inagaki, H. & Ueda, R. (2009) Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunology Immunotherapy, 58, 1195-1206.
76. Izykowska, K. & Przybylski, G.K. (2011) Genetic alterations in Sezary syndrome. Leukemia and Lymphoma, 52, 745-753.
77. Jackow, C.M., McHam, J.B., Friss, A., Alvear, J., Reveille, J.R. & Duvic, M. (1996) HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. Journal of Investigative Dermatology, 107, 373-376.
78. Jaffe, E.S., Harris, N.L., Stein, H. & Isaacson, P.G. (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood, 112, 4384-4399.
79. Jones, D. & Duvic, M. (2003) The current state and future of clonality studies in mycosis fungoides. Journal of Investigative Dermatology, 121, ix-x.
80. Jumbou, O., N'Guyen, J.M., Tessier, M.H., Legoux, B. & Dreno, B. (1999) Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. The British Journal of Dermatology, 140, 427-431.
81. Juvekar, A., Manna, S., Ramaswami, S., Chang, T.P., Vu, H.Y., Ghosh, C.C., Celiker, M.Y. & Vancurova, I. (2011) Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. Molecular Cancer Research, 9, 183-194.
82. Kakinuma, T., Sugaya, M., Nakamura, K., Kaneko, F., Wakugawa, M., Matsushima, K. & Tamaki, K. (2003) Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. Journal of the American Academy of Dermatology, 48, 23-30.
83. Kallinich, T., Muche, J.M., Qin, S., Sterry, W., Audring, H. & Kroczek, R.A. (2003) Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. Journal of Investigative Dermatology, 121, 1045-1052.
84. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J. & Schreiber, R.D. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Science U S A, 95, 7556-7561.
85. Kari, L., Loboda, A., Nebozhyn, M., Rook, A.H., Vonderheid, E.C., Nichols, C., Virok, D., Chang, C., Horng, W.H., Johnston, J., Wysocka, M., Showe, M.K. & Showe, L.C. (2003) Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. Journal of Experimental Medicine, 197, 1477-1488.
86. Kaye, F.J., Bunn, Jr, P.A., Steinberg, S.M., Stocker, J.L., Ihde, D.C., Fischmann, A.B., Glatstein, E.J., Schechter, G.P., Phelps, R.M., Foss, F.M., Parlette, III, H.L., Anderson, M.A. & Sausville, E.A. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine, 321, 1784-1790.
87. Kennah, E., Ringrose, A., Zhou, L.L., Esmailzadeh, S., Qian, H., Su, M.W., Zhou, Y. & Jiang, X. (2009) Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood, 113, 4646-4655.
88. van Kester, M.S., Ballabio, E., Benner, M.F., Chen, X.H., Saunders, N.J., van der Fits, L., van Doorn, R., Vermeer, M.H., Willemze, R., Tensen, C.P. & Lawrie, C.H. (2011) miRNA expression profiling of mycosis fungoides. Molecular Oncology, 5, 273-280.
89. Kim, Y.H. & Hoppe, R.T. (1999) Mycosis fungoides and the Sezary syndrome. Seminars in Oncology, 26, 276-289.
90. Kim, Y.H., Liu, H.L., Mraz-Gernhard, S., Varghese, A. & Hoppe, R.T. (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Archives of Dermatology, 139, 857-866.
91. Kim, Y.H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T.M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K.M., Lisby, S., Baadsgaard, O. & Knox, S.J. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 109, 4655-4662.
92. Kim, Y.H., Girardi, M., Duvic, M., Kuzel, T., Link, B.K., Pinter-Brown, L. & Rook, A.H. (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 63, 975-983.
93. Klein, U. & Dalla-Favera, R. (2008) Germinal centres: role in B-cell physiology and malignancy. Nature Review Immunology, 8, 22-33.
94. Klemke, C.D., Mansmann, U., Poenitz, N., Dippel, E. & Goerdt, S. (2005) Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. British Journal of Dermatology, 153, 118-124.
95. Krejsgaard, T., Ralfkiaer, U., Clasen-Linde, E., Eriksen, K.W., Kopp, K.L., Bonefeld, C.M., Geisler, C., Dabelsteen, S., Wasik, M.A., Ralfkiaer, E., Woetmann, A. & Odum, N. (2011) Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway. Journal of Investigative Dermatology, 131, 1331-1338.
96. Krishnan, S., Warke, V.G., Nambiar, M.P., Wong, H.K., Tsokos, G.C. & Farber, D.L. (2001) Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3zeta expression. Blood, 97, 3851-3859.
97. Kunishige, J.H., McDonald, H., Alvarez, G., Johnson, M., Prieto, V. & Duvic, M. (2009) Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clinical Experimental Dermatology, 34, 576-581.
98. Kurzrock, R., Pilat, S. & Duvic, M. (1999) Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. Journal of Clinical Oncology, 17, 3117-3121.
99. Laharanne, E., Oumouhou, N., Bonnet, F., Carlotti, M., Gentil, C., Chevret, E., Jouary, T., Longy, M., Vergier, B., Beylot-Barry, M. & Merlio, J.P. (2010) Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. Journal of Investigative Dermatology, 130, 1707-1718.
100. Li, G., Yu, M., Weyand, C.M. & Goronzy, J.J. (2009) Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood, 114, 3422-3430.
101. Litvinov, I.V., Jones, D.A., Sasseville, D. & Kupper, T.S. (2010) Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clinical Cancer Research, 16, 2106-2114.
102. Lowes, M.A., Bowcock, A.M. & Krueger, J.G. (2007) Pathogenesis and therapy of psoriasis. Nature, 445, 866-873.
103. Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T. & Osterborg, A. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, 4267-4272.
104. Malamut, G., El Machhour, R., Montcuquet, N., Martin-Lanneree, S., Dusanter-Fourt, I., Verkarre, V., Mention, J.J., Rahmi, G., Kiyono, H., Butz, E.A., Brousse, N., Cellier, C., Cerf-Bensussan, N. & Meresse, B. (2010) IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. Journal of Clinical Investigation, 120, 2131-2143.
105. Mao, X., Orchard, G., Lillington, D.M., Russell-Jones, R., Young, B.D. & Whittaker, S.J. (2003) Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood, 101, 1513-1519.
106. Mao, X., Orchard, G., Lillington, D.M., Child, F.J., Vonderheid, E.C., Nowell, P.C., Bagot, M., Bensussan, A., Russell-Jones, R., Young, B.D. & Whittaker, S.J. (2004) BCL2 and JUNB abnormalities in primary cutaneous lymphomas. British Journal of Dermatology, 151, 546-556.
107. Mao, X., Orchard, G., Vonderheid, E.C., Nowell, P.C., Bagot, M., Bensussan, A., Russell-Jones, R., Young, B.D. & Whittaker, S.J. (2006) Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. Journal of Investigative Dermatology, 126, 1388-1395.
108. Mao, X., Orchard, G., Mitchell, T.J., Oyama, N., Russell-Jones, R., Vermeer, M.H., Willemze, R., van Doorn, R., Tensen, C.P., Young, B.D. & Whittaker, S.J. (2008) A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. Journal of Cutaneous Patholology, 35, 899-910.
109. Marchi, E., Alinari, L., Tani, M., Stefoni, V., Pimpinelli, N., Berti, E., Pagano, L., Bernengo, M.G., Zaja, F., Rupoli, S., Pileri, S., Baccarani, M. & Zinzani, P.L. (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer, 104, 2437-2441.
110. Marie-Cardine, A., Huet, D., Ortonne, N., Remtoula, N., Le Gouvello, S., Bagot, M. & Bensussan, A. (2007) Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome. Blood, 109, 5064-5065.
111. Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. & Kelly, W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nature Review Cancer, 1, 194-202.
112. McCusker, M.E., Garifallou, M. & Bogen, S.A. (1997) Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. Journal of Immunology, 158, 4984-4991.
113. McGinnis, K.S., Junkins-Hopkins, J.M., Crawford, G., Shapiro, M., Rook, A.H. & Vittorio, C.C. (2004) Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. Journal of the American Academy of Dermatology, 50, 375-379.
114. McInturff, J.E., Modlin, R.L. & Kim, J. (2005) The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. Journal of Investigative Dermatology, 125, 1-8.
115. Medenica, M. & Lorincz, A.L. (1978) Pagetoid reticulosis (Woringer-Kolopp disease). Histopathologic and ultrastructural observations. Archives of Dermatology, 114, 262-268.
116. Mirvish, E.D., Pomerantz, R.G. & Geskin, L.J. (2011) Infectious agents in cutaneous T-cell lymphoma. Journal of American Academy of Dermatology, 64, 423-431.
117. Mohr, B., Illmer, T., Oelschlagel, U., Nowak, R., Holig, K., Paaz, U., Kroschinsky, F., Schuler, U. & Ehninger, G. (1996) Complex cytogenetic and immunophenotypic aberrations in a patient with Sezary syndrome. Cancer Genetics Cytogenetics, 90, 33-36.
118. Morales Suarez-Varela, M.M., Llopis Gonzalez, A., Marquina Vila, A. & Bell, J. (2000) Mycosis fungoides: review of epidemiological observations. Dermatology, 201, 21-28.
119. Morales, M.M., Putcha, V., Evans, H.S., Olsen, J., Llopis, A. & Moller, H. (2005) Survival of mycosis fungoides in patients in the Southeast of England. Dermatology, 211, 325-329.
120. Morse, M.A., Hobeika, A.C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H.K. & Clay, T.M. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood, 112, 610-618.
121. Murphy, M., Fullen, D. & Carlson, J.A. (2002) Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. American Journal of Dermatopathology, 24, 6-16.
122. Narducci, M.G., Arcelli, D., Picchio, M.C., Lazzeri, C., Pagani, E., Sampogna, F., Scala, E., Fadda, P., Cristofoletti, C., Facchiano, A., Frontani, M., Monopoli, A., Ferracin, M., Negrini, M., Lombardo, G.A., Caprini, E. & Russo, G. (2011) MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Disease, 2, e151.
123. Ni, X., Hazarika, P., Zhang, C., Talpur, R. & Duvic, M. (2001) Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clinical Cancer Research, 7, 2682-2692.
124. Nickoloff, B.J. (1988) Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. American Journal of Dermatopathology, 10, 469-477.
125. Nunez, V., Alameda, D., Rico, D., Mota, R., Gonzalo, P., Cedenilla, M., Fischer, T., Bosca, L., Glass, C.K., Arroyo, A.G. & Ricote, M. (2010) Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression. Proceedings of the Nattional Academy of Science U S A, 107, 10626-10631.
126. O'Connor, O.A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C.H., Sarasohn, D., Neylon, E., Mastrella, J., Hamelers, R., Macgregor-Cortelli, B., Patterson, M., Seshan, V.E., Sirotnak, F., Fleisher, M., Mould, D.R., Saunders, M. & Zelenetz, A.D. (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of Clinical Oncology, 27, 4357-4364.
127. O'Connor, O.A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K.J., Shustov, A.R., Gisselbrecht, C., Jacobsen, E., Zinzani, P.L., Furman, R., Goy, A., Haioun, C., Crump, M., Zain, J.M., Hsi, E., Boyd, A. & Horwitz, S. (2011) Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: results From the Pivotal PROPEL Study. Journal of Clinical Oncology, 29, 1182-1189.
128. Olsen, E.A. (2003) Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy, 16, 311-321.
129. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P. & Nichols, J. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology, 19, 376-388.
130. Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., Wood, G., Dummer, R., Ranki, A., Burg, G., Heald, P., Pittelkow, M., Bernengo, M.G., Sterry, W., Laroche, L., Trautinger, F. & Whittaker, S. (2007a) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 110, 1713-1722.
131. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. & Duvic, M. (2007b) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
132. Olsen, E.A., Rook, A.H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., Wood, G., Demierre, M.F., Pittelkow, M., Wilson, L.D., Pinter-Brown, L., Advani, R., Parker, S., Kim, E.J., Junkins-Hopkins, J.M., Foss, F., Cacchio, P. & Duvic, M. (2011) Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology, 64, 352-404.
133. O'Mahony, D., Morris, J.C., Stetler-Stevenson, M., Matthews, H., Brown, M.R., Fleisher, T., Pittaluga, S., Raffeld, M., Albert, P.S., Reitsma, D., Kaucic, K., Hammershaimb, L., Waldmann, T.A. & Janik, J.E. (2009) EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clinical Cancer Research, 15, 2514-2522.
134. Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., Kingma, D.M., Turner, M.L., Altemus, R. & Bates, S.E. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 98, 2865-2868.
135. Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S. & Bates, S.E. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103, 4636-4643.
136. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., Zain, J., Prince, H.M., Leonard, J.P., Geskin, L.J., Reeder, C., Joske, D., Figg, W.D., Gardner, E.R., Steinberg, S.M., Jaffe, E.S., Stetler-Stevenson, M., Lade, S., Fojo, A.T. & Bates, S.E. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 27, 5410-5417.
137. Pimpinelli, N., Olsen, E.A., Santucci, M., Vonderheid, E., Haeffner, A.C., Stevens, S., Burg, G., Cerroni, L., Dreno, B., Glusac, E., Guitart, J., Heald, P.W., Kempf, W., Knobler, R., Lessin, S., Sander, C., Smoller, B.S., Telang, G., Whittaker, S., Iwatsuki, K., Obitz, E., Takigawa, M., Turner, M.L. & Wood, G.S. (2005) Defining early mycosis fungoides. Journal of the American Academy of Dermatology, 53, 1053-1063.
138. Pomerantz, R.G., Mirvish, E.D., Erdos, G., Falo, Jr, L.D. & Geskin, L.J. (2010) Novel approach to gene expression profiling in Sezary syndrome. British Journal of Dermatology, 163, 1090-1094.
139. Pope, E., Weitzman, S., Ngan, B., Walsh, S., Morel, K., Williams, J., Stein, S., Garzon, M., Knobler, E., Lieber, C., Turchan, K., Wargon, O. & Tsuchiya, A. (2010) Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. Journal of Cutaneous Medicine and Surgury, 14, 1-6.
140. Posner, L.E., Fossieck, B.E., ., Jr, Eddy., J.L., Bunn. & P.A., Jr, (1981) Septicemic complications of the cutaneous T-cell lymphomas. American Journal of Medicine, 71, 210-216.
141. Poszepczynska-Guigne, E., Schiavon, V., D'Incan, M., Echchakir, H., Musette, P., Ortonne, N., Boumsell, L., Moretta, A., Bensussan, A. & Bagot, M. (2004) CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. Journal of Investigative Dermatology, 122, 820-823.
142. Prince, H.M., Duvic, M., Martin, A., Sterry, W., Assaf, C., Sun, Y., Straus, D., Acosta, M. & Negro-Vilar, A. (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 28, 1870-1877.
143. Pulini, S., Rupoli, S., Goteri, G., Pimpinelli, N., Alterini, R., Tassetti, A., Scortechini, A.R., Offidani, M., Mulattieri, S., Stronati, A., Brandozzi, G., Giacchetti, A., Mozzicafreddo, G., Ricotti, G., Filosa, G., Bettacchi, A., Simonacci, M., Novelli, N. & Leoni, P. (2007) Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica, 92, 686-689.
144. Querfeld, C., Rosen, S.T., Guitart, J., Rademaker, A., Fung, B.B., Posten, W. & Kuzel, T.M. (2004) Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. Journal of the American Academy of Dermatology, 51, 25-32.
145. Rajkumar, S.V., Richardson, P.G., Hideshima, T. & Anderson, K.C. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. Journal of Clinical Oncology, 23, 630-639.
146. Ravat, F.E., Spittle, M.F. & Russell-Jones, R. (2006) Primary cutaneous T-cell lymphoma occurring after organ transplantation. Journal of the American Academy of Dermatology, 54, 668-675.
147. Read, S., Malmstrom, V. & Powrie, F. (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. Journal of Experimental Medicine, 192, 295-302.
148. Richmond, J., Tuzova, M., Parks, A., Adams, N., Martin, E., Tawa, M., Morrison, L., Chaney, K., Kupper, T.S., Curiel-Lewandrowski, C. & Cruikshank, W. (2011) Interleukin-16 as a marker of Sézary syndrome onset and stage. Journal of Clinical Immunology, 31, 39-50.
149. Rider, D.A., Havenith, C.E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J.C., Walker, S., Baadsgaard, O., Marschner, S., vandeWinkel, J.G., Cambier, J., Parren, P.W. & Alexander, D.R. (2007) A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Research, 67, 9945-9953.
150. Robson, A. (2010) Immunocytochemistry and the diagnosis of cutaneous lymphoma. Histopathology, 56, 71-90.
151. Rupoli, S., Goteri, G., Pulini, S., Filosa, A., Tassetti, A., Offidani, M., Filosa, G., Mozzicafreddo, G., Giacchetti, A., Brandozzi, G., Cataldi, I., Barulli, S., Ranaldi, R., Scortechini, A.R., Capretti, R., Fabris, G. & Leoni, P. (2005) Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology, 75, 136-145.
152. Saed, G., Fivenson, D.P., Naidu, Y. & Nickoloff, B.J. (1994) Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. Journal of Investigative Dermatology, 103, 29-33.
153. Samimi, S., Benoit, B., Evans, K., Wherry, E.J., Showe, L., Wysocka, M. & Rook, A.H. (2010) Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Archives of Dermatology, 146, 1382-1388.
154. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J. & Schreiber, R.D. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
155. Shin, J., Monti, S., Aires, D.J., Duvic, M., Golub, T., Jones, D.A. & Kupper, T.S. (2007) Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood, 110, 3015-3027.
156. Sirotnak, F.M., DeGraw, J.I., Colwell, W.T. & Piper, J.R. (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemotherapy and Pharmacology, 42, 313-318.
157. Sterry, W. & Mielke, V. (1989) CD4+ cutaneous T-cell lymphomas show the phenotype of helper/inducer T cells (CD45RA-, CDw29+). Journal of Investigative Dermatology, 93, 413-416.
158. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. & Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105-2112.
159. Su, M.W., Dorocicz, I., Dragowska, W.H., Ho, V., Li, G., Voss, N., Gascoyne, R. & Zhou, Y. (2003) Aberrant expression of T-plastin in Sezary cells. Cancer Research, 63, 7122-7127.
160. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press.
161. Talpur, R., Jones, D.M., Alencar, A.J., Apisarnthanarax, N., Herne, K.L., Yang, Y. & Duvic, M. (2006) CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. Journal of Investigative Dermatology, 126, 575-583.
162. Tan, C. & Waldmann, T.A. (2002) Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Research, 62, 1083-1086.
163. Tang, N., Gibson, H., Germeroth, T., Porcu, P., Lim, H.W. & Wong, H.K. (2010) T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. British Journal of Dermatology, 162, 463-466.
164. Teunissen, M.B., Koomen, C.W., de Waal Malefyt, R., Wierenga, E.A. & Bos, J.D. (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. Journal of Investigative Dermatology, 111, 645-649.
165. Thestrup-Pedersen, K., Hammer, R., Kaltoft, K., Sogaard, H. & Zachariae, H. (1988) Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. British Journal of Dermatology, 118, 811-818.
166. Thomas, L. (1959) Reactions to homologous tissue antigens in relation to hypersensitivity [Discussion]. In: Cellular and Humoral Aspects of the Hypersensitive States (ed. by H. Lawrence ), pp. 529-532. Hoeber-Harper, New York.
167. Tiemessen, M.M., Mitchell, T.J., Hendry, L., Whittaker, S.J., Taams, L.S. & John, S. (2006) Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. Journal of Investigative Dermatology, 126, 2217-2223.
168. Tracey, L., Villuendas, R., Dotor, A.M., Spiteri, I., Ortiz, P., Garcia, J.F., Peralto, J.L., Lawler, M. & Piris, M.A. (2003) Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood, 102, 1042-1050.
169. Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., D'Incan, M., Ranki, A., Pimpinelli, N., Ortiz-Romero, P., Dummer, R., Estrach, T. & Whittaker, S. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. European Journal of Cancer, 42, 1014-1030.
170. Trinchieri, G. (2010) Type I interferon: friend or foe? Journal of Experimental Medicine, 207, 2053-2063.
171. Tsimberidou, A.M., Giles, F., Duvic, M., Fayad, L. & Kurzrock, R. (2004) Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer, 100, 342-349.
172. Vermeer, M.H., van Doorn, R., Dijkman, R., Mao, X., Whittaker, S., van Voorst Vader, P.C., Gerritsen, M.J., Geerts, M.L., Gellrich, S., Soderberg, O., Leuchowius, K.J., Landegren, U., Out-Luiting, J.J., Knijnenburg, J., Ijszenga, M., Szuhai, K., Willemze, R. & Tensen, C.P. (2008) Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Research, 68, 2689-2698.
173. Vonderheid, E.C. (2006) On the diagnosis of erythrodermic cutaneous T-cell lymphoma. Journal of Cutaneous Pathology, 33(Suppl 1), 27-42.
174. Vonderheid, E.C., Tan, E., Sobel, E.L., Schwab, E., Micaily, B. & Jegasothy, B.V. (1987a) Clinical implications of immunologic phenotyping in cutaneous T cell lymphoma. Journal of the American Academy of Dermatology, 17, 40-52.
175. Vonderheid, E.C., Thompson, R., Smiles, K.A. & Lattanand, A. (1987b) Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology, 123, 757-763.
176. Vonderheid, E.C., Bernengo, M.G., Burg, G., Duvic, M., Heald, P., Laroche, L., Olsen, E., Pittelkow, M., Russell-Jones, R., Takigawa, M. & Willemze, R. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. Journal of the American Academy of Dermatology, 46, 95-106.
177. Vowels, B.R., Lessin, S.R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J.T. & Rook, A.H. (1994) Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. Journal of Investigative Dermatology, 103, 669-673.
178. Weaver, C.T., Hatton, R.D., Mangan, P.R. & Harrington, L.E. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Review of Immunology, 25, 821-852.
179. Whittaker, S.J., Demierre, M.F., Kim, E.J., Rook, A.H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J.C., Samtsov, A., McCulloch, W. & Kim, Y.H. (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 28, 4485-4491.
180. Whittemore, A.S., Holly, E.A., Lee, I.M., Abel, E.A., Adams, R.M., Nickoloff, B.J., Bley, L., Peters, J.M. & Gibney, C. (1989) Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. Journal of the National Cancer Institute, 81, 1560-1567.
181. Willemze, R., van Vloten, W.A., Hermans, J., Damsteeg, M.J. & Meijer, C.J. (1983) Diagnostic criteria in Sezary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. Journal of Investigative Dermatology, 81, 392-397.
182. Willemze, R., Jaffe, E.S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz-Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. & Meijer, C.J. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768-3785.
183. Willers, J., Haffner, A., Zepter, K., Storz, M., Urosevic, M., Burg, G. & Dummer, R. (2001) The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. Journal of Investigative Dermatology, 116, 874-879.
184. Wlodarski, M.W., O'Keefe, C., Howe, E.C., Risitano, A.M., Rodriguez, A., Warshawsky, I., Loughran, Jr, T.P. & Maciejewski, J.P. (2005) Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood, 106, 2769-2780.
185. Wollina, U., Graefe, T. & Kaatz, M. (2001) Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up. Annals of the New York Academy of Sciences, 941, 214-216.
186. Wollina, U., Dummer, R., Brockmeyer, N.H., Konrad, H., Busch, J.O., Kaatz, M., Knopf, B., Koch, H.J. & Hauschild, A. (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer, 98, 993-1001.
187. Wong, H.K., Wilson, A.J., Gibson, H.M., Hafner, M.S., Hedgcock, C.J., Berger, C.L., Edelson, R.L. & Lim, H.W. (2006) Increased expression of ctla-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma. Journal of Investigative Dermatology, 126, 212-219.
188. Wood, G.S., Edinger, A., Hoppe, R.T. & Warnke, R.A. (1994) Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. Journal of Cutaneous Pathology, 21, 151-156.
189. Wozniak, M.B., Tracey, L., Ortiz-Romero, P.L., Montes, S., Alvarez, M., Fraga, J., Fernandez Herrera, J., Vidal, S., Rodriguez-Peralto, J.L., Piris, M.A. & Villuendas Deceased, R. (2009) Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology, 160, 92-102.
190. Yamaguchi, T., Ohshima, K., Tsuchiya, T., Suehuji, H., Karube, K., Nakayama, J., Suzumiya, J., Yoshino, T. & Kikuchi, M. (2003) The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma. European Journal of Dermatology, 13, 553-559.
191. Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., Nakamura, S., Inagaki, H., Ohshima, K., Kiyoi, H., Ishida, T., Matsushima, K., Akinaga, S., Ogura, M., Tomonaga, M. & Ueda, R. (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Journal of Clinical Oncology, 28, 1591-1598.
192. Yanagi, T., Shimizu, T., Ujiie, H., Ito, M., Abe, R., Tsuji-Abe, Y., Hige, S. & Shimizu, H. (2006) Peginterferon alfa-2b for mycosis fungoides. Archives of Dermatology, 142, 649-651.
193. Yawalkar, N., Ferenczi, K., Jones, D.A., Yamanaka, K., Suh, K.Y., Sadat, S. & Kupper, T.S. (2003) Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood, 102, 4059-4066.
194. Zinzani, P.L., Magagnoli, M., Bendandi, M., Orcioni, G.F., Gherlinzoni, F., Albertini, P., Pileri, S.A. & Tura, S. (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology, 9, 1351-1353.
195. Zinzani, P.L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., Orcioni, G.F., Ascani, S., Simoni, R., Pileri, S.A. & Tura, S. (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. Journal of Clinical Oncology, 18, 2603-2606.
196. Zinzani, P.L., Alinari, L., Tani, M., Fina, M., Pileri, S. & Baccarani, M. (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica, 90, 702-703.
197. Zinzani, P.L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S. & Baccarani, M. (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 4293-4297.